Glioblastoma — radiation options
17 open options
- TRIALPHASE2RECRUITING
Prophylactic Regimen With Intrathecal Thiotepa in SVZ-positive or Meningeal-risk Glioblastoma
Maximal surgical resection · Concomitant Chemoradiotherapy (Stupp backbone) · Preventive Intrathecal Thiotepa — 1 site
- TRIALPHASE1 / PHASE2RECRUITING
Trial of Anti-PD-1 Immunotherapy and Stereotactic Radiation in Patients With Recurrent Glioblastoma
Pembrolizumab · Stereotactic Radiation Therapy · Surgical Resection — 1 site
- TRIALPHASE1 / PHASE2RECRUITING
A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma
Debio 0123 · Temozolomide · Radiotherapy — 16 sites
- TRIALPHASE1RECRUITING
Study of ABBV-637 or ABBV-155 With ERAS-801 for People With Glioblastoma
ERAS-801 · ABBV-637 · ABBV-155 — 11 sites
- TRIALPHASE1RECRUITING
Atovaquone Combined With Radiation in Children With Malignant Brain Tumors
Atovaquone · Radiation Therapy — 2 sites
- TRIALPHASE2RECRUITING
Retifanlimab with Bevacizumab and Hypofractionated Radiotherapy for the Treatment of Recurrent Glioblastoma
Bevacizumab · Biospecimen Collection · Computed Tomography — 3 sites
- TRIALPHASE1NOT_YET_RECRUITING
Integrating Biology for Safe Intensification of Glioblastoma Hypofractionated Treatment on the MR-Linac
MR-Linac System · Radiation Therapy · Temozolomide — 1 site
- TRIALPHASE2RECRUITING
Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA
Intra-arterial Cetuximab · Intra-arterial Mannitol · Hypofractionated re-irradiation — 1 site
- TRIALPHASE3RECRUITING
Conventional Versus Hypofractionated Radiotherapy With Temozolomide in Elderly Glioblastoma
Hypofractionated radiotherapy · Conventional radiotherapy · Temozolomide — 1 site
- TRIALNARECRUITING
TTFields Plus FET-PET-Guided Stereotactic Radiosurgery Versus TTFields Alone for Recurrent Glioblastoma (Tarrget 2.0)
Tumor Treating Fields (TTFields) · FET-PET-Guided Stereotactic Radiosurgery — 1 site
- TRIALPHASE1 / PHASE2RECRUITING
A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)
Biopsy Procedure · Magnetic Resonance Imaging · Radiation Therapy — 127 sites
- TRIALEARLY_PHASE1RECRUITING
PET-imaging of Two Vartumabs in Patients With Solid Tumors
89Zr-DFO-N-Suc-F8scFv · 89Zr-DFO-N-Suc-C9scFv · PET/CT scan — 1 site
- TRIALNANOT_YET_RECRUITING
Hypofractionated Radiotherapy Plus Temozolamide in Patients Younger Than 70 Years With Glioblastoma
Hypofractionated Radiation Therapy
- TRIALPHASE2RECRUITING
Stupp Treatment With Intrathecal Injection of Thiotepa for Glioblastoma With Advanced Spread
Intrathecal injection of thiotepa · Stupp regimen (oral temozolomide) · Radical radiotherapy — 1 site
- TRIALPHASE1 / PHASE2RECRUITING
Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors
Tarlatamab · Concurrent Radiation Therapy · Sequential Radiation therapy — 2 sites
- TRIALPHASE2RECRUITING
DOC1021 Dendritic Cell Immunotherapy for Treatment of Newly Diagnosed Adult Glioblastoma (GBM)
DOC1021 · Tumor resection · Temodar (Temozolomide) — 18 sites
- TRIALPHASE3RECRUITING
Lomustine With and Without Reirradiation for First Progression of Glioblastoma: a Randomized Phase III Study
Lomustine · Reirradiation — 45 sites
Live from ClinicalTrials.gov, refreshed at most hourly · registry query ↗
Not medical advice. Trial0 is a navigation service, not a medical provider. Nothing here is medical advice or a recommendation to pursue any treatment; eligibility matching is informational, based on published registry criteria, and only the trial site or treating clinician can determine actual eligibility. Decisions belong with the patient and their own doctors.